-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on July 28.
A few days ago, the bevacizumab injection (Ereto) of Hengrui Pharmaceutical's subsidiary Suzhou Shengdia Biopharmaceutical Co.
, Ltd.
was approved by the National Medical Products Administration for the treatment of late stage and metastasis.
Sexual or recurrent non-small cell lung cancer and metastatic colorectal cancer
.
It has only been more than a month since the approval of Erelto for Bevacizumab injection by Boan Biotech was approved for marketing
.
With the addition of Roche, the original research company of Bevacizumab Anvastin, as well as Qilu Pharmaceutical (Enda) and Xinda Pharmaceutical (Dyotong), a total of 5 domestic companies' Bevacizumab has been approved for listing
.
A few days ago, the bevacizumab injection (Ereto) of Hengrui Pharmaceutical's subsidiary Suzhou Shengdia Biopharmaceutical Co.
, Ltd.
was approved by the National Medical Products Administration for the treatment of late stage and metastasis.
Sexual or recurrent non-small cell lung cancer and metastatic colorectal cancer
.
It has only been more than a month since the approval of Erelto for Bevacizumab injection by Boan Biotech was approved for marketing
.
With the addition of Roche, the original research company of Bevacizumab Anvastin, as well as Qilu Pharmaceutical (Enda) and Xinda Pharmaceutical (Dyotong), a total of 5 domestic companies' Bevacizumab has been approved for listing
.
Approved clinically for multiple indications
Avastin, a research drug for bevacizumab single antigen, is the world's first human monoclonal antibody for anti-tumor angiogenesis.
It was developed by Roche Pharmaceuticals and is currently the most studied anti-angiogenic drug.
Its mechanism of action is through Binding with vascular endothelial growth factor (VEGF) prevents VEGF from binding to its natural receptor VEGFR, inhibits the proliferation and activation of vascular endothelial cells, thereby exerting anti-angiogenesis and anti-tumor effects
.
Up to now, Avastin has been approved for marketing in more than 120 countries and regions around the world, and it is a mature therapeutic drug
.
Avastin's approved indications worldwide include non-small cell lung cancer, colorectal cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer and many other cancers
.
It has been approved in China for the treatment of non-small cell lung cancer, colorectal cancer, glioblastoma and liver cancer
.
It was developed by Roche Pharmaceuticals and is currently the most studied anti-angiogenic drug.
Its mechanism of action is through Binding with vascular endothelial growth factor (VEGF) prevents VEGF from binding to its natural receptor VEGFR, inhibits the proliferation and activation of vascular endothelial cells, thereby exerting anti-angiogenesis and anti-tumor effects
.
Up to now, Avastin has been approved for marketing in more than 120 countries and regions around the world, and it is a mature therapeutic drug
.
Avastin's approved indications worldwide include non-small cell lung cancer, colorectal cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer and many other cancers
.
It has been approved in China for the treatment of non-small cell lung cancer, colorectal cancer, glioblastoma and liver cancer
.
Among the bevacizumab currently on the market in China, Anvastin occupies the main market position, accounting for 73.
74%; the second is Qilu Pharmaceutical's Anta, with a market share of 25.
64%; Cinda Pharmaceuticals Dayoutong of the industry was listed late, with a market share of 0.
86%
.
74%; the second is Qilu Pharmaceutical's Anta, with a market share of 25.
64%; Cinda Pharmaceuticals Dayoutong of the industry was listed late, with a market share of 0.
86%
.
In addition to the approved indications, the bevacizumab drug currently under development in China has a number of indications under approval, including the combination of PD-L1 for non-squamous cell non-small cell lung cancer, hepatocellular carcinoma, and metastasis Rectal cancer, unresectable locally advanced cancer
Mucosa or metastatic melanoma, extensive stage small cell lung cancer
.
.
Combined treatment effect "1+1>2 "
Statistics from the International Agency for Research on Cancer (IARC) of the World Health Organization show that in 2020, among the new cancers in China, the top ten cases are lung cancer, colorectal cancer, gastric cancer, breast cancer, liver cancer, esophageal cancer, and thyroid cancer.
, Pancreatic cancer, prostate cancer, and cervical cancer (see figure).
These 10 cancers account for 78% of the total number of new cancers in China
.
Among them, lung cancer, colorectal cancer, breast cancer, and liver cancer are related indications for bevacizumab
.
, Pancreatic cancer, prostate cancer, and cervical cancer (see figure).
These 10 cancers account for 78% of the total number of new cancers in China
.
Among them, lung cancer, colorectal cancer, breast cancer, and liver cancer are related indications for bevacizumab
.
The results of a number of clinical studies at home and abroad have shown that bevacizumab combined with fluoropyrimidine-based chemotherapy can further extend the survival period of patients with colorectal cancer, improve the progression-free survival period, and have good overall safety
.
At present, domestic and foreign guidelines recommend bevacizumab combined with chemotherapy as one of the standard treatment options for first-line, second-line, and maintenance therapy for metastatic colorectal cancer
.
For lung cancer, compared with platinum-containing chemotherapy, bevacizumab combined chemotherapy can prolong the overall survival (OS) and progression-free survival (PFS) of patients with advanced non-small cell lung cancer, and it is well tolerated
.
The combination of bevacizumab and chemotherapy has become one of the first-line standard treatments for advanced non-small cell lung cancer
.
Compared with administration alone, clinical studies have confirmed that the combination of bevacizumab and chemotherapy, targeted therapy, immunotherapy and other programs can bring "1+1>2" anti-tumor efficacy, which can further improve the effectiveness of treatment.
Efficiency, prolong the survival time of cancer patients
.
.
At present, domestic and foreign guidelines recommend bevacizumab combined with chemotherapy as one of the standard treatment options for first-line, second-line, and maintenance therapy for metastatic colorectal cancer
.
For lung cancer, compared with platinum-containing chemotherapy, bevacizumab combined chemotherapy can prolong the overall survival (OS) and progression-free survival (PFS) of patients with advanced non-small cell lung cancer, and it is well tolerated
.
The combination of bevacizumab and chemotherapy has become one of the first-line standard treatments for advanced non-small cell lung cancer
.
Compared with administration alone, clinical studies have confirmed that the combination of bevacizumab and chemotherapy, targeted therapy, immunotherapy and other programs can bring "1+1>2" anti-tumor efficacy, which can further improve the effectiveness of treatment.
Efficiency, prolong the survival time of cancer patients
.
Active layout of local enterprises
As more companies launch bevacizumab, cancer patients will have more treatment options
.
It is estimated that the bevacizumab drug market can reach a sales scale of 10 billion yuan
.
Faced with such a huge market potential, domestic pharmaceutical companies are vying to lay out
.
.
It is estimated that the bevacizumab drug market can reach a sales scale of 10 billion yuan
.
Faced with such a huge market potential, domestic pharmaceutical companies are vying to lay out
.
Judging from the status of bevacizumab already on the market or under investigation (see the table for details), in addition to Hengrui Eruto and Boan Bio-Boyounuo, which have just been marketed, Betta Pharmaceuticals, Biotech, and Toyo Pharmaceuticals The listing applications of Bevacizumab by Industry and Henlius were reviewed by the Drug Evaluation Center of the State Food and Drug Administration from June to September 2020
.
Bevacizumab MI L60 from Bevacizumab is intended for the treatment of patients with advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer; Bevacizumab HLX04 independently developed by Fuhong Hanlin It is mainly used for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer and other diseases
.
In addition, Henlius has also expanded the combination of HLX04 and its own PD-1 monoclonal antibody, and has initiated a key phase III clinical trial of the combination therapy for the first-line treatment of non-squamous non-small cell lung cancer and the second-line treatment for liver cancer.
Phase II clinical trial
.
It is foreseeable that under the background of centralized drug procurement , bevacizumab market competition will become more intense
.
.
Bevacizumab MI L60 from Bevacizumab is intended for the treatment of patients with advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer; Bevacizumab HLX04 independently developed by Fuhong Hanlin It is mainly used for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer and other diseases
.
In addition, Henlius has also expanded the combination of HLX04 and its own PD-1 monoclonal antibody, and has initiated a key phase III clinical trial of the combination therapy for the first-line treatment of non-squamous non-small cell lung cancer and the second-line treatment for liver cancer.
Phase II clinical trial
.
It is foreseeable that under the background of centralized drug procurement , bevacizumab market competition will become more intense
.
Medical Network News on July 28.
A few days ago, the bevacizumab injection (Ereto) of Hengrui Pharmaceutical's subsidiary Suzhou Shengdia Biopharmaceutical Co.
, Ltd.
was approved by the National Medical Products Administration for the treatment of late stage and metastasis.
Sexual or recurrent non-small cell lung cancer and metastatic colorectal cancer
.
It has only been more than a month since the approval of Erelto for Bevacizumab injection by Boan Biotech was approved for marketing
.
With the addition of Roche, the original research company of Bevacizumab Anvastin, as well as Qilu Pharmaceutical (Enda) and Xinda Pharmaceutical (Dyotong), a total of 5 domestic companies' Bevacizumab has been approved for listing
.
A few days ago, the bevacizumab injection (Ereto) of Hengrui Pharmaceutical's subsidiary Suzhou Shengdia Biopharmaceutical Co.
, Ltd.
was approved by the National Medical Products Administration for the treatment of late stage and metastasis.
Sexual or recurrent non-small cell lung cancer and metastatic colorectal cancer
.
It has only been more than a month since the approval of Erelto for Bevacizumab injection by Boan Biotech was approved for marketing
.
With the addition of Roche, the original research company of Bevacizumab Anvastin, as well as Qilu Pharmaceutical (Enda) and Xinda Pharmaceutical (Dyotong), a total of 5 domestic companies' Bevacizumab has been approved for listing
.
Approved clinically for multiple indications
Avastin, a research drug for bevacizumab single antigen, is the world's first human monoclonal antibody for anti-tumor angiogenesis.
It was developed by Roche Pharmaceuticals and is currently the most studied anti-angiogenic drug.
Its mechanism of action is through Binding with vascular endothelial growth factor (VEGF) prevents VEGF from binding to its natural receptor VEGFR, inhibits the proliferation and activation of vascular endothelial cells, thereby exerting anti-angiogenesis and anti-tumor effects
.
Up to now, Avastin has been approved for marketing in more than 120 countries and regions around the world, and it is a mature therapeutic drug
.
Avastin's approved indications worldwide include non-small cell lung cancer, colorectal cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer and many other cancers
.
It has been approved in China for the treatment of non-small cell lung cancer, colorectal cancer, glioblastoma and liver cancer
.
It was developed by Roche Pharmaceuticals and is currently the most studied anti-angiogenic drug.
Its mechanism of action is through Binding with vascular endothelial growth factor (VEGF) prevents VEGF from binding to its natural receptor VEGFR, inhibits the proliferation and activation of vascular endothelial cells, thereby exerting anti-angiogenesis and anti-tumor effects
.
Up to now, Avastin has been approved for marketing in more than 120 countries and regions around the world, and it is a mature therapeutic drug
.
Avastin's approved indications worldwide include non-small cell lung cancer, colorectal cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer and many other cancers
.
It has been approved in China for the treatment of non-small cell lung cancer, colorectal cancer, glioblastoma and liver cancer
.
Among the bevacizumab currently on the market in China, Anvastin occupies the main market position, accounting for 73.
74%; the second is Qilu Pharmaceutical's Anta, with a market share of 25.
64%; Cinda Pharmaceuticals Dayoutong of the industry was listed late, with a market share of 0.
86%
.
74%; the second is Qilu Pharmaceutical's Anta, with a market share of 25.
64%; Cinda Pharmaceuticals Dayoutong of the industry was listed late, with a market share of 0.
86%
.
In addition to the approved indications, the bevacizumab drug currently under development in China has a number of indications under approval, including the combination of PD-L1 for non-squamous cell non-small cell lung cancer, hepatocellular carcinoma, and metastasis Rectal cancer, unresectable locally advanced cancer
Mucosa or metastatic melanoma, extensive stage small cell lung cancer
.
.
Combined treatment effect "1+1>2 "
Statistics from the International Agency for Research on Cancer (IARC) of the World Health Organization show that in 2020, among the new cancers in China, the top ten cases are lung cancer, colorectal cancer, gastric cancer, breast cancer, liver cancer, esophageal cancer, and thyroid cancer.
, Pancreatic cancer, prostate cancer, and cervical cancer (see figure).
These 10 cancers account for 78% of the total number of new cancers in China
.
Among them, lung cancer, colorectal cancer, breast cancer, and liver cancer are related indications for bevacizumab
.
, Pancreatic cancer, prostate cancer, and cervical cancer (see figure).
These 10 cancers account for 78% of the total number of new cancers in China
.
Among them, lung cancer, colorectal cancer, breast cancer, and liver cancer are related indications for bevacizumab
.
The results of a number of clinical studies at home and abroad have shown that bevacizumab combined with fluoropyrimidine-based chemotherapy can further extend the survival period of patients with colorectal cancer, improve the progression-free survival period, and have good overall safety
.
At present, domestic and foreign guidelines recommend bevacizumab combined with chemotherapy as one of the standard treatment options for first-line, second-line, and maintenance therapy for metastatic colorectal cancer
.
For lung cancer, compared with platinum-containing chemotherapy, bevacizumab combined chemotherapy can prolong the overall survival (OS) and progression-free survival (PFS) of patients with advanced non-small cell lung cancer, and it is well tolerated
.
The combination of bevacizumab and chemotherapy has become one of the first-line standard treatments for advanced non-small cell lung cancer
.
Compared with administration alone, clinical studies have confirmed that the combination of bevacizumab and chemotherapy, targeted therapy, immunotherapy and other programs can bring "1+1>2" anti-tumor efficacy, which can further improve the effectiveness of treatment.
Efficiency, prolong the survival time of cancer patients
.
.
At present, domestic and foreign guidelines recommend bevacizumab combined with chemotherapy as one of the standard treatment options for first-line, second-line, and maintenance therapy for metastatic colorectal cancer
.
For lung cancer, compared with platinum-containing chemotherapy, bevacizumab combined chemotherapy can prolong the overall survival (OS) and progression-free survival (PFS) of patients with advanced non-small cell lung cancer, and it is well tolerated
.
The combination of bevacizumab and chemotherapy has become one of the first-line standard treatments for advanced non-small cell lung cancer
.
Compared with administration alone, clinical studies have confirmed that the combination of bevacizumab and chemotherapy, targeted therapy, immunotherapy and other programs can bring "1+1>2" anti-tumor efficacy, which can further improve the effectiveness of treatment.
Efficiency, prolong the survival time of cancer patients
.
Active layout of local enterprises
As more companies launch bevacizumab, cancer patients will have more treatment options
.
It is estimated that the bevacizumab drug market can reach a sales scale of 10 billion yuan
.
Faced with such a huge market potential, domestic pharmaceutical companies are vying to lay out
.
.
It is estimated that the bevacizumab drug market can reach a sales scale of 10 billion yuan
.
Faced with such a huge market potential, domestic pharmaceutical companies are vying to lay out
.
Judging from the status of bevacizumab already on the market or under investigation (see the table for details), in addition to Hengrui Eruto and Boan Bio-Boyounuo, which have just been marketed, Betta Pharmaceuticals, Biotech, and Toyo Pharmaceuticals The listing applications of Bevacizumab by Industry and Henlius were reviewed by the Drug Evaluation Center of the State Food and Drug Administration from June to September 2020
.
Bevacizumab MI L60 from Bevacizumab is intended for the treatment of patients with advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer; Bevacizumab HLX04 independently developed by Fuhong Hanlin It is mainly used for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer and other diseases
.
In addition, Henlius has also expanded the combination of HLX04 and its own PD-1 monoclonal antibody, and has initiated a key phase III clinical trial of the combination therapy for the first-line treatment of non-squamous non-small cell lung cancer and the second-line treatment for liver cancer.
Phase II clinical trial
.
It is foreseeable that under the background of centralized drug procurement , bevacizumab market competition will become more intense
.
.
Bevacizumab MI L60 from Bevacizumab is intended for the treatment of patients with advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer; Bevacizumab HLX04 independently developed by Fuhong Hanlin It is mainly used for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer and other diseases
.
In addition, Henlius has also expanded the combination of HLX04 and its own PD-1 monoclonal antibody, and has initiated a key phase III clinical trial of the combination therapy for the first-line treatment of non-squamous non-small cell lung cancer and the second-line treatment for liver cancer.
Phase II clinical trial
.
It is foreseeable that under the background of centralized drug procurement , bevacizumab market competition will become more intense
.
Medical Network News on July 28.
A few days ago, the bevacizumab injection (Ereto) of Hengrui Pharmaceutical's subsidiary Suzhou Shengdia Biopharmaceutical Co.
, Ltd.
was approved by the National Medical Products Administration for the treatment of late stage and metastasis.
Sexual or recurrent non-small cell lung cancer and metastatic colorectal cancer
.
It has only been more than a month since the approval of Erelto for Bevacizumab injection by Boan Biotech was approved for marketing
.
With the addition of Roche, the original research company of Bevacizumab Anvastin, as well as Qilu Pharmaceutical (Enda) and Xinda Pharmaceutical (Dyotong), a total of 5 domestic companies' Bevacizumab has been approved for listing
.
A few days ago, the bevacizumab injection (Ereto) of Hengrui Pharmaceutical's subsidiary Suzhou Shengdia Biopharmaceutical Co.
, Ltd.
was approved by the National Medical Products Administration for the treatment of late stage and metastasis.
Sexual or recurrent non-small cell lung cancer and metastatic colorectal cancer
.
It has only been more than a month since the approval of Erelto for Bevacizumab injection by Boan Biotech was approved for marketing
.
With the addition of Roche, the original research company of Bevacizumab Anvastin, as well as Qilu Pharmaceutical (Enda) and Xinda Pharmaceutical (Dyotong), a total of 5 domestic companies' Bevacizumab has been approved for listing
.
Approved clinically for multiple indications
Approved clinically for multiple indications Avastin, a research drug for bevacizumab single antigen, is the world's first human monoclonal antibody for anti-tumor angiogenesis.
It was developed by Roche Pharmaceuticals and is currently the most studied anti-angiogenic drug.
Its mechanism of action is through Binding with vascular endothelial growth factor (VEGF) prevents VEGF from binding to its natural receptor VEGFR, inhibits the proliferation and activation of vascular endothelial cells, thereby exerting anti-angiogenesis and anti-tumor effects
.
Up to now, Avastin has been approved for marketing in more than 120 countries and regions around the world, and it is a mature therapeutic drug
.
Avastin's approved indications worldwide include non-small cell lung cancer, colorectal cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer and many other cancers
.
It has been approved in China for the treatment of non-small cell lung cancer, colorectal cancer, glioblastoma and liver cancer
.
It was developed by Roche Pharmaceuticals and is currently the most studied anti-angiogenic drug.
Its mechanism of action is through Binding with vascular endothelial growth factor (VEGF) prevents VEGF from binding to its natural receptor VEGFR, inhibits the proliferation and activation of vascular endothelial cells, thereby exerting anti-angiogenesis and anti-tumor effects
.
Up to now, Avastin has been approved for marketing in more than 120 countries and regions around the world, and it is a mature therapeutic drug
.
Avastin's approved indications worldwide include non-small cell lung cancer, colorectal cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian cancer and many other cancers
.
It has been approved in China for the treatment of non-small cell lung cancer, colorectal cancer, glioblastoma and liver cancer
.
Among the bevacizumab currently on the market in China, Anvastin occupies the main market position, accounting for 73.
74%; the second is Qilu Pharmaceutical's Anta, with a market share of 25.
64%; Cinda Pharmaceuticals Dayoutong of the industry was listed late, with a market share of 0.
86%
.
74%; the second is Qilu Pharmaceutical's Anta, with a market share of 25.
64%; Cinda Pharmaceuticals Dayoutong of the industry was listed late, with a market share of 0.
86%
.
In addition to the approved indications, the bevacizumab drug currently under development in China has a number of indications under approval, including the combination of PD-L1 for non-squamous cell non-small cell lung cancer, hepatocellular carcinoma, and metastasis Rectal cancer, unresectable locally advanced cancer
Mucosa or metastatic melanoma, extensive stage small cell lung cancer
.
.
Combined treatment effect "1+1>2 "
Combined treatment effect "1+1>2 " Statistics from the International Agency for Research on Cancer (IARC) of the World Health Organization show that in 2020, among the new cancers in China, the top ten cases are lung cancer, colorectal cancer, gastric cancer, breast cancer, liver cancer, esophageal cancer, and thyroid cancer.
, Pancreatic cancer, prostate cancer, and cervical cancer (see figure).
These 10 cancers account for 78% of the total number of new cancers in China
.
Among them, lung cancer, colorectal cancer, breast cancer, and liver cancer are related indications for bevacizumab
.
, Pancreatic cancer, prostate cancer, and cervical cancer (see figure).
These 10 cancers account for 78% of the total number of new cancers in China
.
Among them, lung cancer, colorectal cancer, breast cancer, and liver cancer are related indications for bevacizumab
.
The results of a number of clinical studies at home and abroad have shown that bevacizumab combined with fluoropyrimidine-based chemotherapy can further extend the survival period of patients with colorectal cancer, improve the progression-free survival period, and have good overall safety
.
At present, domestic and foreign guidelines recommend bevacizumab combined with chemotherapy as one of the standard treatment options for first-line, second-line, and maintenance therapy for metastatic colorectal cancer
.
For lung cancer, compared with platinum-containing chemotherapy, bevacizumab combined chemotherapy can prolong the overall survival (OS) and progression-free survival (PFS) of patients with advanced non-small cell lung cancer, and it is well tolerated
.
The combination of bevacizumab and chemotherapy has become one of the first-line standard treatments for advanced non-small cell lung cancer
.
Compared with administration alone, clinical studies have confirmed that the combination of bevacizumab and chemotherapy, targeted therapy, immunotherapy and other programs can bring "1+1>2" anti-tumor efficacy, which can further improve the effectiveness of treatment.
Efficiency, prolong the survival time of cancer patients
.
Standard Standard Standard.
At present, domestic and foreign guidelines recommend bevacizumab combined with chemotherapy as one of the standard treatment options for first-line, second-line, and maintenance therapy for metastatic colorectal cancer
.
For lung cancer, compared with platinum-containing chemotherapy, bevacizumab combined chemotherapy can prolong the overall survival (OS) and progression-free survival (PFS) of patients with advanced non-small cell lung cancer, and it is well tolerated
.
The combination of bevacizumab and chemotherapy has become one of the first-line standard treatments for advanced non-small cell lung cancer
.
Compared with administration alone, clinical studies have confirmed that the combination of bevacizumab and chemotherapy, targeted therapy, immunotherapy and other programs can bring "1+1>2" anti-tumor efficacy, which can further improve the effectiveness of treatment.
Efficiency, prolong the survival time of cancer patients
.
Active layout of local enterprises
Local business enterprise enterprises active layout As more companies launch bevacizumab, cancer patients will have more treatment options
.
It is estimated that the bevacizumab drug market can reach a sales scale of 10 billion yuan
.
Faced with such a huge market potential, domestic pharmaceutical companies are vying to lay out
.
.
It is estimated that the bevacizumab drug market can reach a sales scale of 10 billion yuan
.
Faced with such a huge market potential, domestic pharmaceutical companies are vying to lay out
.
Judging from the status of bevacizumab already on the market or under investigation (see the table for details), in addition to Hengrui Eruto and Boan Bio-Boyounuo, which have just been marketed, Betta Pharmaceuticals, Biotech, and Toyo Pharmaceuticals The listing applications of Bevacizumab by Industry and Henlius were reviewed by the Drug Evaluation Center of the State Food and Drug Administration from June to September 2020
.
Bevacizumab MI L60 from Bevacizumab is intended for the treatment of patients with advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer; Bevacizumab HLX04 independently developed by Fuhong Hanlin It is mainly used for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer and other diseases
.
In addition, Henlius has also expanded the combination of HLX04 and its own PD-1 monoclonal antibody, and has initiated a key phase III clinical trial of the combination therapy for the first-line treatment of non-squamous non-small cell lung cancer and the second-line treatment for liver cancer.
Phase II clinical trial
.
It is foreseeable that under the background of centralized drug procurement , bevacizumab market competition will become more intense
.
Drugs Drugs Drugs disease disease disease Procurement Purchasing Procurement.
Bevacizumab MI L60 from Bevacizumab is intended for the treatment of patients with advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer; Bevacizumab HLX04 independently developed by Fuhong Hanlin It is mainly used for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer and other diseases
.
In addition, Henlius has also expanded the combination of HLX04 and its own PD-1 monoclonal antibody, and has initiated a key phase III clinical trial of the combination therapy for the first-line treatment of non-squamous non-small cell lung cancer and the second-line treatment for liver cancer.
Phase II clinical trial
.
It is foreseeable that under the background of centralized drug procurement , bevacizumab market competition will become more intense
.
